SnoN as a novel negative regulator of TGF-β/Smad signaling: A target for tailoring organ fibrosis

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 308, Issue 1, 2015, Pages H75-H82

  Zeglinski, Matthew R ^a   Hnatowich, Mark ^a   Jassal, Davinder S ^a   Dixon, Ian M C ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Fibrosis; Myofibroblast; SnoN; TGF 1< inf>

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; MATRIX PROTEIN; NERVE CELL ADHESION MOLECULE; REGULATOR PROTEIN; SKI PROTEIN; SMAD PROTEIN; SNO PROTEIN; SNON PROTEIN; SUMO PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; COLLAGEN; ONCOPROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

AMINO ACID SEQUENCE; CATALYSIS; CELL SURVIVAL; CYTOPLASM; EXTRACELLULAR MATRIX; FIBROSIS; GENE CONTROL; GENE OVEREXPRESSION; GENE SILENCING; HEART; HEART FIBROBLAST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; KIDNEY FIBROSIS; LIVER; LUNG; MUSCLE DEVELOPMENT; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; TISSUE INJURY; VERTEBRATE; ANIMAL; CHEMISTRY; GENETICS; HEART MUSCLE; METABOLISM; PATHOLOGY;

ANIMALS; COLLAGEN; FIBROSIS; HUMANS; LUNG; MYOCARDIUM; PROTO-ONCOGENE PROTEINS; SMAD PROTEINS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84920103031     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00453.2014     Document Type: Review

References (85)

1. Berk M, Dcsai SY, Heynian HC, Colmenares C. Mice lacking the ski proto-oncogene have defects in neurulation, craniofacial, patterning, and skeletal muscle development. Genes Dev 11: 2029-2039, 1997.
2. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, Kottkamp H, Dhein S. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 90: 400-405, 2004.
3. Boyer PL, Colmenares C, Stavnezcr E, Hughes SH. Sequence and biological activity of chicken snoN cDNA clones. Oncogene 8: 457-466, 1993.
4. Brand T, Schneider MD. The TGF beta superfamily in myocardium: ligands, receptors, transduction, and function. J Mol Cell Cardiol 27: 5-18, 1995.
5. Brand T, Schneider MD. Transforming growth factor-beta signal transduction. Circ Res 78: 173-179, 1996.
6. Cai Y, Shen XZ, Zhou CH, Wang JY. Abnormal expression of Smurf2 during the process of rat liver fibrosis. Chin J Dig Dis 7: 237-245, 2006.
7. Carmignac V, Thevenon J, Ades L, Callewaert B, Julia S, Thauvin- Robinet C, Gueneau L, Courcet JB, Lopez E, Holman K, Renard M, Plauchu H, Piessis G, De Backer J, Child A, Arno G, Duplumb L, Callicr P, Aral B, Vabres P, Gigot N, Arbustini E, Grasso M, Robinson PN, Goizet C, Baumann C, Di Rocco M, Sanchez Del Pozo J, Huet F, Jondeau G, Collod-Beroud G, Beroud C, Amicl J, Cormicr-Daire V, Riviere J.B, Boileau C, De Paepe A, Faivre L. In-frame mutations in exon 1 of SKI cause dominant Shprintzen-Goldberg syndrome. Am J Hum Genet 91: 950-957, 2012.
8. Chen J, Zeng T, Zhao X, Xiea K, Bi Y, Zhong Z, Zhao X. Docosa- hexaenoic acid (DHA) ameliorates paraquat-induced pulmonary fibrosis in rats possibly through up-regulation of Smad 7 and SnoN. Food Chem Toxicol 57: 330-337, 2013.
9. Chen Y, Pirisi L, Creek KE. Ski protein levels increase during in vitro progression of HPV16-immortalized human keratinocytes and in cervical cancer. Virology 444: 100-108, 2013.
10. Cohen SB, Zheng G, Heynian HC, Stavnezer E. Heterodimers of the SnoN and Ski oncoproteins form preferentially over homodimers and are more potent transforming agents. Nucleic Acids Res 27: 1006-1014, 1999.
11. Cunnington RH, Nazari M, Dixon IM. c-Ski, Smurf2, and Arkadia as regulators of TGF-beta signaling: new targets for managing myofibroblast function and cardiac fibrosis. Can J Physiol Pharmacol 87: 764 -772, 2009.
12. Cunnington RH, Wang B, Ghavami S, Bathe KL, Rattan SG, Dixon IM. Antiíìbrotic properties of c-Ski and its regulation of cardiac myofibroblast phenotype and contractility. Am J Physiol Cell Physiol 300: CI76-C186, 2011.
13. Deheuninck J, Luo K. Ski and SnoN, potent negative regulators of TGF-beta signaling. Cell Res 19: 47-57, 2009.
14. Dixon IM, Wang B, Bedosky K, Cunnington RH, Rattan SG, Almaqrhi A. Regulatory role of TGF-b in cardiac myofibroblast function and post-MI cardiac fibrosis: key role of Smad7 and c-Ski. In: Advances in Biochemistry in Health and Disease (ABHD): Focus on Signal Transduction in Cardiovascular System in Health and Disease, edited by Srivastava AKA-S and Madhu B. (Eds.) New York: Springer Verlag, vol. 3, 2008.
15. Fddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301, 2000.
16. Fiedler J, Thuni T. MicroRNAs in myocardial infarction. Arterioscler Thromb Vase Biol 33: 201-205, 2013.
17. Franklin TJ. Therapeutic approaches to organ fibrosis. Int J Biochem Cell Biol 29: 79-89, 1997.
18. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol 38, Suppl 1: S38-S53, 2003.
19. Fukasawa H, Yamamoto T, Togawa A, Ohashi N, Fujigaki Y, Oda T, Uchida C, Kitagawa K, Hattori T, Suzuki S, Kitagawa M, llishida A. Ubiquitin-dependent degradation of SnoN and Ski is increased in renal fibrosis induced by obstructive injury. Kidney hit 69: 1733-1740, 2006.
20. Gay SE, Kazerooni EA, Toews GB, Lynch JP 3rd, Gross BH, Cascade PN, Spizarny DL, Flint A, Schork MA, Whyte RI, Popüvich J, Hyzy R, Martinez FJ. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 157: 1063-1072, 1998.
21. Ghosh AK, Quaggin SE, Vaughan DE. Molecular basis of organ fibrosis: potential therapeutic approaches. Exp Biol Med (Maywood) 238: 461-481. 2013.
22. Harada J, Kokura K, Kanei-Ishii C, Nomura T, Khan MM, Kim Y, Ishii S. Requirement of the co-repressor homeodomain-interacting protein kinase 2 for ski-mediated inhibition of bone morphogenetic protein- induced transcriptional activation. J Biol Chem 278: 38998-39005, 2003.
23. Hayashi H, Abdullah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, Topper JN, Gimbrvne MA Jr, Wrana JL, Falb D. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 89: 1165-1173, 1997.
24. He J, Tegen SB, Krawitz AR, Martin GS, Luo K. The transforming activity of Ski and SnoN is dependent on their ability to repress the activity of Smad proteins. J Biol Chem 278: 30540-30547, 2003.
25. Hewitson TD. Fibrosis in the kidney: is a problem shared a problem halved? Fibrogenesis Tissue Repair 5: S14, 2012.
26. Heyman HC, Stavnezer E. A carboxyl-terminal region of the ski oncoprotein mediates homodimerization as well as heterodimerization with the related protein SnoN. J Biol Chem 269: 26996-27003, 1994.
27. Hsu YH, Sarker KP, Pot I, Chan A, Netherton SJ, Bonni S. Sumoy- lated SnoN represses transcription in a promoter-specific manner. J Biol Chem 281: 33008-33018, 2006.
28. Jahchan NS, Luo K. SnoN in mammalian development, function and diseases. Curr Opin Pharmacol 10: 670-675, 2010.
29. Jahchan NS, Ouyang G, Luo K. Expression profiles of SnoN in normal and cancerous human tissues support its tumor suppressor role in human cancer. PloS One 8: e55794, 2013.
30. Jahchan NS, You YH, Muller WJ, Luo K. Transforming growth factor-beta regulator SnoN modulates mammary gland branching morphogenesis, postlactational involution, and mammary tumorigenesis. Cancer Res 70: 4204-4213, 2010.
31. Jiang H, Jin C, Liu J, Hua D, Zhou F, Lou X, Zhao N, Lan Q, Huang O, Yoon JG, Zheng S, Lin B. Next generation sequencing analysis of miRNAs: MiR-127-3p inhibits glioblastoma proliferation and activates TGF-beta signaling by targeting SKI. OMICS 18: 196-206, 2014.
32. Kimura S, Asaka M, Atsumi H, Imura J, Fujinioto K, Chikazawa Y, Nakagawa M, Okuyama H, Yamaya H, Yokoyama H. Circulating fibrocytes in ischemia-reperfusion injury and chronic renal allograft fibrosis. Nephron Clin Pracl 121: c16-c24, 2012.
33. Kingsley DM. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 8: 133-146, 1994.
34. Kishore R, Vernia SK, Mackie AR, Vaughan EE, Abramova TV, Aiko I, Krishnamurthy P. Bone marrow progenitor cell therapy-mediated paracrine regulation of cardiac miRNA-155 modulates fibrotic response in diabetic hearts. PloS One 8: e60161, 2013.
35. Kokura K, Kaul SC, Wadhwa R, Nomura T, Khan MM, Shinagawa T, Yasukawa T, Colmenares C, Ishii S. The Ski protein family is required for MeCP2-mediated transcriptional repression. J Biol Chem 276: 34115-34121, 2001.
36. Krakowski AR, Laboureau J, Mauviel A, Bisseil MJ, Luo K. Cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-beta signaling by sequestration of the Smad proteins. Proc Nall Acad Sci USA 102: 12437-12442, 2005.
37. Leong GM, Kee AJ, Millard SM, Martel N, Eriksson N, Turner N, Cooney GJ, Hardeman EC, Muscat GE. The Ski proto-oncogene regulates body composition and suppresses lipogenesis. Int J Obes (Lond) 34: 524-536, 2010.
38. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Ini 69: 213-217, 2006.
39. Luo K. Ski and SnoN: negative regulators of TGF-beta signaling. Curr Opin Genet Dev 14: 65-70, 2004.
40. Macias-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL. MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 87: 1215-1224, 1996.
41. Marquez-Aguirre A, Sandovai-Rodriguez A, Gonzalez-Cuevas J, Bueno-Topete M, Navarro-Partida J, Arellano-Olivera I, Lucano- Landeros S, Armcndariz-Iiorunda J. Adenoviral delivery of dominant- negative transforming growth factor beta type II receptor up-regulates transcriptional repressor SKl-like oncogene, decreases matrix metallopro- teinase 2 in hepatic stellate cell and prevents liver fibrosis in rats. J Gene Med 11: 207-219, 2009.
42. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 166: 675-684, 2005.
43. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389: 631-635, 1997.
44. Nguyen TP, Qu Z, Weiss JN. Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. J Mol Cell Cardiol 70: 83-91, 2014.
45. Nomura N, Sasamoto S, Ishii S, Date T, Matsui M, Ishizaki R. Isolation of human cDNA clones of ski and the ski-related gene, sno. Nucleic Acids Res 17: 5489-5500, 1989.
46. Nomura T, Khan MM, Kaul SC, Dong HD, Wadhwa R, Colmenares C, Kohno I, Ishii S. Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor. Genes Dev 13: 412-423, 1999.
47. Pan D, Zhu Q, Luo K. SnoN functions as a tumour suppressor by inducing premature senescence. EM BO J 28: 3500-3513, 2009.
48. Park SH. Fine tuning and cross-talking of TGF-beta signal by inhibitory Smads. J Biochem Mol Biol 38: 9-16, 2005.
49. Patel V, Noureddine L. MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens 21: 410-416, 2012.
50. Pearson-White S. Snol, a novel alternatively spliced isoform of the ski protooncogene homolog, sno. Nucleic Acids Res 21: 4632-4638, 1993.
51. Pearson-White S, Crittenden R. Proto-oncogene Sno expression, alternative isoforms and immediate early serum response. Nucleic Acids Res 25: 2930-2937, 1997.
52. Pearson-White S, McDuffie M. Defective T-cell activation is associated with augmented transforming growth factor Beta sensitivity in mice with mutations in the Sno gene. Mol Cell Biol 5446-5459, 2003.
53. Pelzer T, Lyons GE, Kim S, Moreadith RW. Cloning and characterization of the murine homolog of the sno proto-oncogene reveals a novel splice variant. Dev Dyn 205: 114-125, 1996.
54. Schepers D, Doyle AJ, Oswald G, Sparks E, Myers L, Willems PJ, Mansour S, Simpson MA, Frysira H, Maat-Kievit A, Van Minkelen R, Hoogeboom JM, Mortier GR, Titheradge H, Brueton L, Starr L, Stark Z, Ockeloen C, Lourenco CM, Blair E, Hobson E, Hurst J, Maystadt I, Destree A, Girisha KM, Miller M, Dietz HC, Loeys B, Van Laer L. The SMAD-binding domain of SKI: a hotspot for de novo mutations causing Shprintzen-Goldberg syndrome. Eur J Hum Genet. 2014 Apr 16. doi: 10.1038/ejhg.2014.61. [Epub ahead of print]
55. Scholten D, Rcichart D, Paik YH, Lindcrt J, Bhattacharya J, Glass CK, Brenner DA, Kisseleva T. Migration of fibrocytes in fibrogenic liver injury. Am J Pathol 179: 189-198, 2011.
56. Seok HY, Chen J, Kataoka M, Huang ZP, Ding J, Yan J, llu X, Wang DZ. Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy. Circ Res 114: 1585-1595, 2014.
57. Shinagawa T, Dong HD, Xu M, Maekawa T, Ishii S. The sno gene, which encodes a component of the histone deacetylase complex, acts as a tumor suppressor in mice. EMBO J 19: 2280-2291, 2000.
58. Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science 286: 771-774, 1999.
59. Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling. Proc Nall Acad Sci USA 96: 12442-12447, 1999.
60. Takaesu NT, Ilyman-Walsh C, Ye Y, Wisotzkey RG, Stinchlield MJ, O'Connor MB, Wotton D, Newfeld SJ. dSno facilitates baboon signaling in the Drosophila brain by switching the affinity of Medea away from Mad and toward dSmad2. Genetics 174: 1299-1313, 2006.
61. Tan AY, Zimetbaum P. Atrial fibrillation and atrial fibrosis. J Crdiovasc Pharmacol 57: 625-629, 2011.
62. Tan R, He W, Lin X, Kiss LP, Liu Y. Smad ubiquitination regulatory factor-2 in the fibrotic kidney: regulation, target specificity, and functional implication. Am J Physiol Renal Physiol 294: F1076-FI083, 2008.
63. Tan R, Zhang J, Tan X, Zhang X, Yang J, Liu Y. Downregulation of SnoN expression in obstructive nephropathy is mediated by an enhanced ubiquìtin-dependent degradation. J Am Sac Nephrol 17: 2781-2791, 2006.
64. Tecalco-Cruz AC, Sosa-Garrocho M, Vazqucz-Victorio G, Ortiz- Garcia L, Dominguez-Huttinger E, Macias-Silva M. Transforming growth factor-beta/SMAD Target gene SKIL is negatively regulated by the transcriptional cofactor complex SNON-SMAD4. J Biol Chem 287: 26764-26776, 2012.
65. Tijsen AJ, van der Made I, van den Hoogenhof MM, Wijnen WJ, van Deel KD, de Groot NE, Alekseev S, Fluiter K, Schroen B, Goumans MJ, van der Velden J, Duncker DJ, Pinto YM, Creemers EE. The microRNA-15 family inhibits the TGFbeta-pathway in the heart. Cardiovasc Res 104: 61-71, 2014.
66. Van der Werf A, Van Assel S, Aerts D, Steinert M, Pays E. Telomere interactions may condition the programming of antigen expression in Trypanosoma brucei. EMBO J 9: 1035-1040, 1990.
67. Wang L, Hou Y, Sun Y, Zhao L, Tang X, Hu P, Yang J, Zeng Z, Yang G, Cul X, Liu M. c-Ski activates cancer-associated fibroblasts to regulate breast cancer cell invasion. Mol Oncol 7: 1116-1128, 2013.
68. Weng T, Poth JM, Karmouty-Quintana H, Garcia-Morales LJ, Melicoff E, Luo F, Chen NY, Evans CM, Bunge RR, Bruckner BA, Loebe M, Volcik KA, Eltzschig HK, Blackburn MR. Hypoxia-induced deoxy- cytidine kinase contributes to epithelial proliferation in pulmonary fibrosis. Am J Respir Crit Care Med. 2014 Oct 30. [Epub ahead of print]
69. Whitman M. Signal transduction. Feedback from inhibitory SMADs. Nature 389: 549-551, 1997.
70. Wilson JJ, Malakhova M, Zhang R, Joachimiak A, Hegde RS. Crystal structure of the dachshund homology domain of human SKI. Structure 12: 785-792, 2004.
71. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal ìmmunol 2: 103-121, 2009.
72. Wrana JL. Regulation of Smad activity. Cell 100: 189-192, 2000.
73. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta receptor. Nature 370: 341-347, 1994.
74. Wrighlon KH, Liang M, Bryan B, Luo K, Liu M, Feng XH, Lin X. Transforming growth factor-beta-independent regulation of myogenesis by SnoN sumoylation. J Biol Chem 282: 6517-6524, 2007.
75. Wu JW, Krawitz AR, Chai J, Li W, Zhang F, Luo K, Shi Y. Structural mechanism of Smad4 recognition by the nuclear oncoprotein Ski: insights on Ski-mediated repression of TGF-beta signaling. Cell 111: 357-367, 2002.
76. Wu K, Yang Y, Wang C, Davoli MA, D'Amico M, Li A, Cveklova K, Kozmik Z, Lisanti MP, Russell RG, Cvekl A, Peslell RG. DACHI inhibits transforming growth factor-beta signaling through binding Smad4. J Biol Chem 278: 51673-51684, 2003.
77. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18: 1028-1040, 2012.
78. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172, 2009.
79. Yang J, Dai C, Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol 16: 68-78, 2005.
80. Yang J, Zhang X, Li Y, Liu Y. Downregulation of Smad transcriptional corepressors SnoN and Ski in the fibrotic kidney: an amplification mechanism for TGF-beta 1 signaling. J Am Soc Nephrol 14: 3167-3177, 2003.
81. Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res 89: 744-753, 2011.
82. Yue X, Shan B, Lasky JA. TGF-beta: titan of lung fibrogenesis. Curr Eenzym Inhib 6: 2010.
83. Zhang X, Egawa K, Xie Y, Ihn H. The expression of SnoN in normal human skin and cutaneous keratinous neoplasms. Int J Dermatol 48: 579-583, 2009.
84. Zhang Y, Feng X, We R, Derynck R. Receptor-associated Mad homo- logues synergize as effectors of the TGF-beta response. Nature 383: 168-172, 1996.
85. Zheng G. Blumenthal KM, Ji Y, Shardy DL, Cohen SB, Stavnezer E. High affinity dimerization by Ski involves parallel pairing of a novel bipartite alpha-helical domain. J Biol Chem 272: 31855-31864, 1997.